NASDAQ:NTGN Neon Therapeutics Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.07 0.00 (0.00 %) (As of 05/6/2020) Add Compare Share Today's Range$3.07Now: $3.07▼$3.0750-Day Range$2.77MA: $3.03▼$3.0752-Week Range$0.88Now: $3.07▼$6.25VolumeN/AAverage Volume516,108 shsMarket Capitalization$88.93 millionP/E RatioN/ADividend YieldN/ABeta-0.81 ProfileAnalyst RatingsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingNeon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.06, Neon Therapeutics has a forecasted upside of 130.0% from its current price of $3.07.Amount of Analyst CoverageNeon Therapeutics has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNeon Therapeutics has received 169 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeon Therapeutics has received 160 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeon Therapeutics has received 51.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote “Outperform” if you believe NTGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeon Therapeutics does not currently pay a dividend.Dividend GrowthNeon Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.93% of the stock of Neon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.71% of the stock of Neon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neon Therapeutics are expected to grow in the coming year, from ($1.33) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neon Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neon Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeon Therapeutics has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTGN Previous Symbol CUSIPN/A CIKN/A Webwww.neontherapeutics.com Phone617-337-4701Employees102 Debt Debt-to-Equity Ratio0.43 Current Ratio1.58 Quick Ratio3.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.14Profitability EPS (Most Recent Fiscal Year)($2.86) Net Income$-79,780,000.00 Net MarginsN/A Return on Equity-199.09% Return on Assets-137.14%Miscellaneous Outstanding Shares28,967,000Market Cap$88.93 million Next Earnings DateN/A OptionableNot Optionable Receive NTGN News and Ratings via Email Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter. Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Neon Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neon Therapeutics. How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) announced its quarterly earnings results on Monday, March, 2nd. The company reported ($0.63) EPS for the quarter, beating the Zacks' consensus estimate of ($0.66) by $0.03. View Neon Therapeutics' earnings history. What price target have analysts set for NTGN? 5 Wall Street analysts have issued 12-month price targets for Neon Therapeutics' stock. Their forecasts range from $2.18 to $12.00. On average, they expect Neon Therapeutics' stock price to reach $7.06 in the next year. This suggests a possible upside of 130.0% from the stock's current price. View analysts' price targets for Neon Therapeutics. Who are some of Neon Therapeutics' key competitors? Some companies that are related to Neon Therapeutics include Cellular Biomedicine Group (CBMG), Innate Pharma (IPHA), Rubius Therapeutics (RUBY), Prevail Therapeutics (PRVL), Surface Oncology (SURF), Precision BioSciences (DTIL), Brainstorm Cell Therapeutics (BCLI), CASI Pharmaceuticals (CASI), Innate Pharma (IPHYF), Jounce Therapeutics (JNCE), Cabaletta Bio (CABA), Eiger BioPharmaceuticals (EIGR), Checkmate Pharmaceuticals (CMPI), PDL BioPharma (PDLI) and Pluristem Therapeutics (PSTI). View all competitors. What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Pfizer (PFE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), T2 Biosystems (TTOO) and Vaxart (VXRT). Who are Neon Therapeutics' key executives? Neon Therapeutics' management team includes the following people: Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)Dr. Eric S. Lander, Founder & Director (Age 62)Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)Dr. Richard Gaynor, Pres of R&D (Age 69)Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer When did Neon Therapeutics IPO? (NTGN) raised $101 million in an initial public offering on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager. What is Neon Therapeutics' stock symbol? Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN." What is Neon Therapeutics' stock price today? One share of NTGN stock can currently be purchased for approximately $3.07. How big of a company is Neon Therapeutics? Neon Therapeutics has a market capitalization of $88.93 million. The company earns $-79,780,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe. What is Neon Therapeutics' official website? The official website for Neon Therapeutics is www.neontherapeutics.com. How can I contact Neon Therapeutics? Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected] This page was last updated on 10/31/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
